Approved medicines Human randomized trial Metabolic health
Also discussed as: Victoza, Saxenda
What it is and how it works
Liraglutide acts at GLP-1 receptors, which help regulate appetite and glucose-related signaling. The same active ingredient can appear in products with different indications; the molecule name is only part of the medical context.
Source for the mechanism context →A closer look at the cited evidence
Human randomized trial
This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.
- Study or assessment
- Pi-Sunyer et al., 2015 — SCALE weight-management trial
- Design
- Randomized, placebo-controlled trial; 56 weeks.
- Who or what was studied
- 3,731 adults without type 2 diabetes who met the study’s weight-related eligibility criteria.
- What was observed
- Liraglutide with lifestyle intervention produced greater average weight reduction than placebo with lifestyle intervention.
- Limits of interpretation
- A study average is not a guarantee. This trial does not establish safety or effectiveness for a different product or every population.
What the evidence means
Human clinical evidence supports labeled uses rather than a general wellness claim.
Approval and regulatory context
Specific products are FDA approved for diabetes or weight management. Eligibility and indications differ by product.
Safety and uncertainty
A clinician must assess suitability and explain the current product warnings; this profile is not a complete safety summary.
What remains uncertain
An approved indication is narrower than a claim that a compound is good for everyone. Current labeling, the exact diagnosis, and individual medical history are needed for a clinician’s assessment; this profile cannot supply that assessment.
These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.
Sources behind this overview
- NIH / NIDDK: prescription medicines and weight management
- Pi-Sunyer et al., 2015 — SCALE weight-management trial
- DailyMed — Saxenda mechanism and safety
Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.